Skip to main content
SpringerLink
Log in

Economic Evaluation of Primary HIV Prevention in Injection Drug Users

  • Chapter
Handbook of Economic Evaluation of HIV Prevention Programs

Part of the book series: AIDS Prevention and Mental Health ((APMH))

Abstract

In 1998, injecting drug users are the most important risk group in the AIDS epidemic. Injecting drug users (IDUs) themselves account for 26% of all newly reported AIDS cases1 and are estimated to represent 50% of new HIV infections.2 In addition, HIV infections in IDUs spread in quantitatively important ways to other population groups. For example, women whose risk factor is being the sex partner of IDUs constitute 4% of all new AIDS cases.1 These women may in turn transmit the virus to other sex partners and to their offspring.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 1996; 9(no. 1): Table 3.

    Google Scholar 

  2. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996; 86: 642–654.

    Article  CAS  PubMed  Google Scholar 

  3. Higgins DL, Galavotti C, O’Reilly KR, et al. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA 1991; 266: 2419–2429.

    Article  CAS  PubMed  Google Scholar 

  4. Auerbach JD, Wypijewska C, Brodie HKH, eds. AIDS and Behavior: An Integrated Approach. Institute of Medicine. Washington, DC: National Academy Press, 1994, pp. 100–109.

    Google Scholar 

  5. Choi KH, Coates TJ. Editorial review: Prevention of HIV infection. AIDS 1994; 8:1371–1389.

    Article  CAS  PubMed  Google Scholar 

  6. Booth RE, Watters JK. Editorial review: How effective are risk reduction interventions targeting injecting drug users? AIDS 1994; 8: 1515–1524.

    Article  CAS  PubMed  Google Scholar 

  7. Des Jarlais DC, Padian N, Winkelstein W. Targeted versus generalized AIDS prevention programming in the United States (oral presentation). Presented at the AAAS Meeting; San Francisco, CA; February 1994.

    Google Scholar 

  8. Des Jarlais DC, Friedman SR, Sotheran JL, et al. Continuity and change within an HIV epidemic: Injecting drug users in New York City, 1984 through 1992. JAMA 1994; 271(2): 121–127.

    Article  PubMed  Google Scholar 

  9. Kahn JG, Washington AE, Showstack JA, Berlin M, Phillips K. Updated Estimates of the Impact and Cost of HIV Prevention in Injection Drug Users. Report prepared for the Centers for Disease Control and Prevention. San Francisco: Institute for Health Policy Studies, University of California at San Francisco, 1992.

    Google Scholar 

  10. Guinan ME, Franham PG, Holtgrave DR. Estimating the value of preventing a human immunodeficiency virus infection. Am J Preventive Med 1993; 10: 1–4.

    Google Scholar 

  11. Kahn JG. The cost-effectiveness of HIV prevention targeting: How much more bang for the buck? Am J Public Health 1996; 86: 1709–1712.

    Article  CAS  PubMed  Google Scholar 

  12. Gleghorn AA, Doherty MC, Vlahov D, et al. Inadequate bleach contact times during syringe cleaning among injection drug users. J Acquired Immune Defic Syndr 1994; 7: 767–772.

    CAS  Google Scholar 

  13. Titus S, Marmor M, Des Jarlais D, et al. Bleach use and HIV seroconversion among New York City injection drug users. J Acquired Immune Defic Syndr 1994; 7: 700–704.

    CAS  Google Scholar 

  14. Vlahov D, Muñoz A, Celentano DD, et al. HIV seroconversion and disinfection of injection equipment among intravenous drug users, Baltimore, Maryland. Epidemiology 1991; 2: 444–446.

    Article  CAS  PubMed  Google Scholar 

  15. Shapshak P, McCoy CB, Shah SM, et al. Preliminary laboratory studies of inactivation of HIV-1 in needles and syringes containing infected blood using undiluted household bleach. J Acquired Immune Defic Syndr 1994; 7: 754–759.

    CAS  Google Scholar 

  16. Contoreggi C, Jones SW, Simpson PM, et al. A model of syringe disinfection as measured by polymerase chain reaction for human leukocyte antigen and HIV genome. Eighth International Conference on AIDS, Amsterdam, 1992, Abstract P.C. 4280; 2:C291.

    Google Scholar 

  17. Watters JK, Cheng Y-T, Segal M, et al. Epidemiology and prevention of HIV in heterosexual IV drug users in San Francisco, 1986–1989. (Oral Presentation). Sixth International Conference on AIDS. San Francisco, 1990. Abstract F.C. 106.

    Google Scholar 

  18. Office of Technology Assessment. AIDS-related Issues. The effectiveness of drug abuse treatment: Implications for controlling AIDS/HIV infection. Washington, DC: U.S. Government, 1990: 1–114.

    Google Scholar 

  19. Hubbard RL, Marsden ME, Rachal JV, et al. Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill, NC University of North Carolina Press; 1989.

    Google Scholar 

  20. Kahn JG. “Chapter 18: Are NEPs cost-effective in preventing HIV infection?” In Lurie P, Reingold AL, eds. The public health impact of needle exchange programs in the United States and abroad. Report prepared for the Centers for Disease Control and Prevention, School of Public Health, University of California, Berkeley and Institute for Health Policy Studies, University of California, San Francisco, 1993.

    Google Scholar 

  21. Kaplan EH. Economic analysis of needle exchange. AIDS 1995; 9: 1113–1119.

    Article  CAS  PubMed  Google Scholar 

  22. Kaplan EH. Back-of-the-envelope estimates of needle exchange effectiveness (working paper), 1993.

    Google Scholar 

  23. Kahn JG, Haynes-Sanstad K. Meaningful standards: Making good decisions about HIV prevention. AIDS Public Policy J 1997; 12: 21–30.

    CAS  PubMed  Google Scholar 

  24. Lurie P, Drucker E. An opportunity lost: HIV infections associated with the lack of a national needle-exchange programme in the USA. Lancet 1997; 349: 604–608.

    Article  CAS  PubMed  Google Scholar 

  25. Lurie P, Gorsky RD, Jones TS, et al. Assessing the cost-effectiveness of needle exchange and pharmacy-based programs to increase sterile syringe availability for injection drug users (IDUs). Presented at Workshop on Sterile Needles and Syringes for Drug Users who Continue Injecting, Baltimore, MD, February 16, 1995.

    Google Scholar 

  26. Richter A, Brandeau ML, Owens DK. Optimal resource allocation for HIV prevention: An application to the Menlo Park/Palo Alto VA Hospital (working paper).

    Google Scholar 

  27. Kaplan EH, Brandeau ML. AIDS policy modeling by example. AIDS 1994; 8(Suppl. l): S333–S340.

    Google Scholar 

  28. Kahn JG. “Chapter 8: What do NEPs cost?”. In Lurie P, Reingold AL, eds. The public health impact of needle exchange programs in the United States and abroad. Report prepared for the Centers for Disease Control and Prevention, School of Public Health, University of California, Berkeley and Institute for Health Policy Studies, University of California, San Francisco, 1993.

    Google Scholar 

  29. Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277(2): 145–153.

    Article  CAS  PubMed  Google Scholar 

  30. Kaplan EH. Economic evaluation and HIV prevention community planning—a policy analyst’s perspective. In Holtgrave D, ed. Handbook of Economic Evaluation of HIV Prevention Programs, New York: Plenum Press, 1998.

    Google Scholar 

  31. Des Jarlais DC, Hagan H, Friedman SR, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA 1995; 274(15): 1226–1231.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for AIDS Prevention Studies, Institute for Health Policy Studies, and Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, San Francisco, California, 94109, USA

    James G. Kahn

Authors
  1. James G. Kahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Behavioral Medicine, Center for AIDS Intervention Research (CAIR), Medical College of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, 53202, USA

    David R. Holtgrave Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kahn, J.G. (1998). Economic Evaluation of Primary HIV Prevention in Injection Drug Users. In: Holtgrave, D.R. (eds) Handbook of Economic Evaluation of HIV Prevention Programs. AIDS Prevention and Mental Health. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1878-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-1878-9_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-1880-2

  • Online ISBN: 978-1-4899-1878-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation